Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.

AIMS To create a general physiologically based pharmacokinetic (PBPK) model for drug disposition in infants and children, covering the age range from birth to adulthood, and to evaluate it with theophylline and midazolam as model drugs. METHODS Physiological data for neonates, 0.5-, 1-, 2-, 5-, 10- and 15-year-old children, and adults, of both sexes were compiled from the literature. The data comprised body weight and surface area, organ weights, vascular and interstitial spaces, extracellular body water, organ blood flows, cardiac output and glomerular filtration rate. Tissue: plasma partition coefficients were calculated from rat data and unbound fraction (f u) of the drug in human plasma, and age-related changes in unbound intrinsic hepatic clearance were estimated from CYP1A2 and CYP2E1 (theophylline) and CYP3A4 (midazolam) activities in vitro. Volume of distribution (V dss), total and renal clearance (CL and CL R) and elimination half-life (t(1/2)) were estimated by PBPK modelling, as functions of age, and compared with literature data. RESULTS The predicted V dss of theophylline was 0.4-0.6 l kg(-1) and showed only a modest change with age. The median prediction error (MPE) compared with literature data was 3.4%. Predicted total CL demonstrated the time-course generally reported in the literature. It was 20 ml h(-1) kg(-1) in the neonate, rising to 73 ml h(-1) kg(-1) at 5 years and then decreasing to 48 ml h(-1) kg(-1) in the adult. Overall, the MPE was - 4.0%. Predicted t(1/2) was 18 h in the neonate, dropping rapidly to 4.6-7.2 h from 6 months onwards, and the MPE was 24%. The predictions for midazolam were also in good agreement with literature data. V dss ranged between 1.0 and 1.7 l kg(-1) and showed only modest change with age. CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult. Predicted t(1/2) was 6.9 h in the neonate and attained 'adult' values of 2.5-3.5 h from 1 year onwards. CONCLUSIONS A general PBPK model for the prediction of drug disposition over the age range neonate to young adult is presented. A reference source of physiological data was compiled and validated as far as possible. Since studies of pharmacokinetics in children present obvious practical and ethical difficulties, one aim of the work was to utilize maximally already available data. Prediction of the disposition of theophylline and midazolam, two model drugs with dissimilar physicochemical and pharmacokinetic characteristics, yielded results that generally tallied with literature data. Future use of the model may demonstrate further its strengths and weaknesses.

[1]  M. V. St-Pierre,et al.  Temporal variation in the disposition of theophylline and its metabolites , 1985, Clinical pharmacology and therapeutics.

[2]  A. Freiburghaus,et al.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450. , 1995, British journal of clinical pharmacology.

[3]  L. Sansom,et al.  A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission , 2004, European Journal of Clinical Pharmacology.

[4]  E. Widdowson,et al.  Chemical changes in skeletal muscle during development. , 1960, The Biochemical journal.

[5]  B. Persson,et al.  CEREBRAL BLOOD FLOW AND EXCHANGE OF OXYGEN, GLUCOSE, KETONE BODIES, LACTATE, PYRUVATE AND AMINO ACIDS IN INFANTS , 1976, Acta paediatrica Scandinavica.

[6]  G. Schwartz,et al.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.

[7]  Meindert Danhof,et al.  Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.

[8]  Nafziger An,et al.  Sex-related differences in theophylline pharmacokinetics. , 1989 .

[9]  J. Takeda,et al.  LIVER BLOOD FLOW DURING HIGH FREQUENCY OSCILLATION AND CONVENTIONAL MECHANICAL VENTILATION , 1984 .

[10]  R. Ogilvie,et al.  Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. , 1976, The Journal of pediatrics.

[11]  E. Widdowson,et al.  The effect of growth and function on the chemical composition of soft tissues. , 1960, The Biochemical journal.

[12]  Dale Hattis,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Caffeine and Theophylline in Neonates and Adults: Implications for Assessing Children's Risks from Environmental Agents , 2004, Journal of toxicology and environmental health. Part A.

[13]  É. Jacqz-Aigrain,et al.  Pharmacokinetics of midazolam in critically ill neonates , 2004, European Journal of Clinical Pharmacology.

[14]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[15]  H. Boxenbaum Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  C. Whight,et al.  Echo Doppler assessment of cardiac output and its relation to growth in normal infants. , 1987, The American journal of cardiology.

[17]  Shinichi Kobayashi,et al.  Developmental Changes in Urinary Elimination of Theophylline and Its Metabolites in Pediatric Patients , 1999, Pediatric Research.

[18]  M. J. Eadie,et al.  The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.

[19]  T. Cresteil,et al.  Delayed ontogenesis of CYP1A2 in the human liver. , 1998, European journal of biochemistry.

[20]  L. Paalzow,et al.  Pharmacokinetics of theophylline in Ethiopian children of differing nutritional status , 2004, European Journal of Clinical Pharmacology.

[21]  F. Tinahones,et al.  Adipose tissue fatty acids and size and number of fat cells from birth to 9 years of age--a cross-sectional study in 96 boys. , 1996, Metabolism: clinical and experimental.

[22]  M. Relling,et al.  Hepatic drug clearance in children: studies with indocyanine green as a model substrate. , 1989, Journal of pharmaceutical sciences.

[23]  S. Riegelman,et al.  Nonlinear theophylline elimination , 1982, Clinical pharmacology and therapeutics.

[24]  N. Baber,et al.  Dose estimation for children. , 2003, British journal of clinical pharmacology.

[25]  Harvey J Clewell,et al.  Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. , 2003, Regulatory toxicology and pharmacology : RTP.

[26]  S. Haddad,et al.  Physiological Modeling of Age-Specific Changes in the Pharmacokinetics of Organic Chemicals in Children , 2003, Journal of toxicology and environmental health. Part A.

[27]  W. Jusko,et al.  Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding. , 1989, Biopharmaceutics & drug disposition.

[28]  J. Dundee,et al.  A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. , 1988, British journal of anaesthesia.

[29]  B. K. Park,et al.  Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. , 1988, The Journal of pharmacology and experimental therapeutics.

[30]  M Pelekis,et al.  Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. , 2001, Regulatory toxicology and pharmacology : RTP.

[31]  G Benoni,et al.  Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. , 2001, Journal of pharmaceutical sciences.

[32]  T. Cresteil,et al.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.

[33]  B. Friis‐Hansen WATER DISTRIBUTION IN THE FOETUS AND NEWBORN INFANT , 1983, Acta paediatrica Scandinavica. Supplement.

[34]  G. L. Baker Human adipose tissue composition and age. , 1969, The American journal of clinical nutrition.

[35]  J. Fluhr,et al.  Direct Comparison of Skin Physiology in Children and Adults with Bioengineering Methods , 2000, Pediatric dermatology.

[36]  Sovitj Pou,et al.  The Single‐Dose Pharmacokinetics of Midazolam and Its Primary Metabolite in Pediatric Patients after Oral and Intravenous Administration , 2001, Journal of clinical pharmacology.

[37]  K. Mcculloch,et al.  Alterations in theophylline metabolism during the first year of life , 1993, Clinical pharmacology and therapeutics.

[38]  Paul Y. K. Wu,et al.  Peripheral Blood Flow in the Neonate. 1. Changes in Total, Skin, and Muscle Blood Flow with Gestational and Postnatal Age , 1980, Pediatric Research.

[39]  T. Cresteil,et al.  Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. , 1996, European journal of biochemistry.

[40]  F. Simons,et al.  Pharmacokinetics of Theophylline in Infancy , 1978, Journal of clinical pharmacology.

[41]  N. Butte,et al.  Body Composition during the First 2 Years of Life: An Updated Reference , 2000, Pediatric Research.

[42]  R. Ogilvie,et al.  Pharmacokinetics of intravenous theophylline , 1973, Clinical pharmacology and therapeutics.

[43]  Jane Alcorn,et al.  Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants Part I , 2002, Clinical pharmacokinetics.

[44]  O. Linderkamp,et al.  Estimation and prediction of blood volume in infants and children , 1977, European Journal of Pediatrics.

[45]  D. Greenblatt,et al.  Effect of Age, Gender, and Obesity on Midazolam Kinetics , 1984, Anesthesiology.

[46]  D. Back,et al.  Theophylline metabolism in human liver microsomes: inhibition studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[47]  R. Leggett,et al.  Reference values for resting blood flow to organs of man. , 1989, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.

[48]  F. Haschke,et al.  Body composition of reference children from birth to age 10 years. , 1982, The American journal of clinical nutrition.

[49]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[50]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[51]  M. Weinberger,et al.  Relationship of theophylline clearance to oral dosage in children with chronic asthma. , 1977, The Journal of pediatrics.

[52]  T. Turmen,et al.  Pharmacokinetics of diuretics and methylxanthines in the neonate , 1980, European Journal of Clinical Pharmacology.

[53]  J. Magny,et al.  Population pharmacokinetics of midazolam in neonates , 1994, Clinical pharmacology and therapeutics.

[54]  D. Agbaba,et al.  Dependence of the Renal Excretion of Theophylline on its Plasma Concentrations and Urine Flow Rate in Asthmatic Children , 1990, The Journal of pharmacy and pharmacology.

[55]  Kannan Krishnan,et al.  CHARACTERIZATION OF AGE-RELATED CHANGES IN BODY WEIGHT AND ORGAN WEIGHTS FROM BIRTH TO ADOLESCENCE IN HUMANS , 2001, Journal of toxicology and environmental health. Part A.

[56]  W. Jusko,et al.  Theophylline tissue partitioning and volume of distribution in normal and dietary-induced obese rats. , 1987, Biopharmaceutics & drug disposition.

[57]  M. Rubin,et al.  Maturation of renal function in childhood; clearance studies. , 1949, The Journal of clinical investigation.